Estimating the Prevalence and Unravelling the Disease Mechanisms of GNE Myopathy
| dc.contributor.author | Derksen, Alexa | |
| dc.contributor.supervisor | Lochmüller, Hanns | |
| dc.date.accessioned | 2026-11-18T17:33:39Z | |
| dc.date.issued | 2026-11-18 | |
| dc.description.abstract | GNE myopathy (GNEM) is a rare autosomal recessive neuromuscular disorder caused by biallelic pathogenic variants in GNE, which encodes a bifunctional enzyme essential for sialic acid biosynthesis. GNEM is characterized by progressive skeletal muscle weakness that begins in early adulthood, with relative sparing of the quadriceps. Despite advances in understanding the genetic basis of GNEM, the disease remains underdiagnosed, lacks reproducible animal models that faithfully recapitulate the human phenotype, has no validated biomarkers or disease-modifying therapies, and its pathogenic mechanisms remain incompletely understood. This thesis aimed to advance the understanding of GNEM by investigating its prevalence, molecular pathogenesis, and the development of human disease models. First, the prevalence of GNEM was estimated using GNE variant frequencies from healthy population databases. A comprehensive catalogue of pathogenic GNE variants was compiled through a systematic review of the literature and variant databases and expanded using in silico pathogenicity assessments of variants of uncertain significance. Population allele frequencies from the gnomAD database were subsequently used to estimate GNEM prevalence, which ranged from 11.00 to 87.68 cases per million. These findings suggest that GNEM is substantially more common than previously recognized. Second, proteomic analyses identified serglycin as a potential circulating biomarker of GNEM. Reduced serum serglycin in patients was accompanied by intracellular accumulation in GNEM cellular models. Further investigation implicated disruptions in membrane trafficking, Golgi function, protein secretion, lysosomal pathways, and autophagic flux as potential mechanisms underlying this dysregulation. Finally, patient-derived induced pluripotent stem cells (iPSCs) were differentiated into skeletal muscle, motor neurons, and three-dimensional neuromuscular organoids to establish human models of GNEM. Although these models demonstrated preserved neuromuscular development, including muscle and neuronal differentiation and neuromuscular junction formation, disease-associated phenotypes emerged with maturation, including progressive vacuolar pathology, altered autophagic-lysosomal homeostasis, mitochondrial abnormalities, and impaired electrically evoked contractile function. Collectively, this work demonstrates that GNEM is likely under recognized, identifies serglycin as a promising candidate biomarker, provides new insights into disease mechanisms, and establishes human iPSC-based models that will facilitate future studies of disease pathogenesis and therapeutic development. | |
| dc.identifier.uri | http://hdl.handle.net/10393/52243 | |
| dc.language.iso | en | |
| dc.publisher | Université d'Ottawa / University of Ottawa | |
| dc.subject | GNE Myopathy | |
| dc.subject | Neuromuscular Disease | |
| dc.subject | Genetics | |
| dc.subject | Biomarkers | |
| dc.subject | Cell Models | |
| dc.title | Estimating the Prevalence and Unravelling the Disease Mechanisms of GNE Myopathy | |
| dc.type | Thesis | en |
| thesis.degree.discipline | Médecine / Medicine | |
| thesis.degree.level | Doctoral | |
| thesis.degree.name | PhD | |
| uottawa.department | Médecine cellulaire et moléculaire / Cellular and Molecular Medicine |
